Vaccitech
Oxford vaccine spinout, renamed Barinthus Biotherapeutics in 2023
100X Meter Early
Think Vaccitech could go 100X?
Give it a push. One tap per reader each day; the meter tracks buzz here, not quality.
Tell your network you backed Vaccitech early
Download share card
For founders
Share your listing
Everything you need to send people to Vaccitech on 100xFounder. Links carry share tags so you can see the visits in your own analytics.
Badge for your site
Shows your live 100X Meter level and links to this page.
Share card
A 1080×1350 image with your current level, sized for Instagram and LinkedIn.
Download share cardReady-to-post captions
We're listed on 100xFounder. Vaccitech now has a page on the 100X Meter, where readers back the startups they believe in with one tap a day.
If you've used Vaccitech, a tap or a short review there would mean a lot to the team: https://100xfounder.com/startup/vaccitech/?utm_source=linkedin&utm_medium=share&utm_campaign=founder-kit
X
Vaccitech is on the 100xFounder 100X Meter ⚡ Think we could go 100X? One tap a day helps: https://100xfounder.com/startup/vaccitech/?utm_source=x&utm_medium=share&utm_campaign=founder-kit
Hi! Vaccitech is listed on 100xFounder. If you like what we're building, tap "100X it" on our page (takes two seconds, once a day): https://100xfounder.com/startup/vaccitech/?utm_source=whatsapp&utm_medium=share&utm_campaign=founder-kit
Invite your users to back you on the 100X Meter
Each reader can tap once a day. Send this to your users, community or newsletter.
What Vaccitech does
Vaccitech was a biotechnology company spun out of the University of Oxford’s Jenner Institute in 2016. Its early work included the co-invention and early development of the Oxford/AstraZeneca COVID-19 vaccine, Vaxzevria. The company later listed on Nasdaq.
On 6 November 2023 Vaccitech announced that it had changed its name to Barinthus Biotherapeutics, trading under the ticker BRNS from 7 November. The company said the old name suggested a purely vaccine-focused business, while its work had moved to T-cell immunotherapies for infectious diseases, autoimmunity and cancer. The new name comes from a figure in the Arthurian legends described as a guide and navigator. The old vaccitech.co.uk address now redirects to barinthusbio.com.
In 2026 the company’s lead programme is VTP-1000, an experimental treatment for coeliac disease. Barinthus said enrolment in the Phase 1 AVALON trial was complete with 42 subjects, and that topline data from its multiple-ascending-dose part were expected in the fourth quarter of 2026. For the second quarter of 2026 it reported a net loss of $10.6 million and cash of $59.6 million at 30 June.
On 30 September 2025 Barinthus and Clywedog Therapeutics announced an all-stock merger. Under the original terms, Barinthus shareholders would own about 34% of the combined company and Clywedog’s about 66%; the combined business would be renamed Clywedog Therapeutics and trade on Nasdaq as CLYD. The merger agreement was amended in February 2026, and the company’s later filings still describe the deal as pending. We have not seen confirmation that it has closed.
This is a drug developer, not a product you can buy. It appears on 100xFounder as part of our coverage of startups and their outcomes.
This profile is put together from the company’s own pages and published reporting, checked on 15 October 2026. We have not tested the product, and nothing here is paid placement.
What people use Vaccitech for
- Following an Oxford biotech spinout from vaccines to immunotherapy
- Tracking the Barinthus and Clywedog merger
- Researching coeliac disease treatments in development (VTP-1000)
Vaccitech pricing
Not applicable: Barinthus Biotherapeutics develops experimental medicines and has no products on sale.
Checked 15 October 2026 · Official pricing page · Prices change, so confirm before you buy
Who Vaccitech is for
- follow biotech companies and university spinouts
- invest in or research Nasdaq-listed biotechs (this is not investment advice)
- are looking for a product or service to buy
Vaccitech pros and cons
- Oxford Jenner Institute origins
- Lead programme in coeliac disease with data due in Q4 2026
- Loss-making, clinical-stage company
- Pending merger will change its name and ownership again
Vaccitech alternatives and how they compare
Other companies working on immune-system therapies or with a similar Oxford viral-vector background.
| Product | What it is | Starts at | Reviews | How it differs from Vaccitech |
|---|---|---|---|---|
| Vaccitech this page | Oxford vaccine spinout, renamed Barinthus Biotherapeutics in 2023 | Not applicable | No reviews yet | — |
| Clywedog Therapeutics | Biotech focused on metabolic and autoimmune diseases | See its own pricing page | — | Barinthus's merger partner. |
| Anokion | Biotech developing tolerance therapies for autoimmune disease | See its own pricing page | — | Also developing treatments for coeliac disease. |
| Oxford Biomedica | Viral-vector manufacturing company | See its own pricing page | — | Manufactured the Oxford/AstraZeneca vaccine at scale; a service provider rather than a drug developer. |
Vaccitech reviews
Write a review
Thanks — share your take?
Frequently asked questions
What happened to Vaccitech?
It renamed itself Barinthus Biotherapeutics in November 2023 and now trades on Nasdaq as BRNS.
Did Vaccitech make the Oxford COVID vaccine?
It co-invented and did early development work on the Oxford/AstraZeneca vaccine, Vaxzevria, which AstraZeneca developed and sold.
Is Barinthus merging with another company?
Yes. In September 2025 it agreed an all-stock merger with Clywedog Therapeutics; the combined company is to be called Clywedog Therapeutics. The deal was still pending in the company's latest filings we saw.
Sources (5), checked 15 October 2026
- Barinthus: Vaccitech renames as Barinthus Biotherapeutics (press release)
- Fierce Biotech: Vaccitech re-emerges as Barinthus
- SEC Form 8-K: merger agreement with Clywedog (Sept 2025)
- Barinthus Q1 2026 results (SEC exhibit)
- Quiver Quant: Barinthus Q2 2026 net loss as Clywedog merger advances
We list Vaccitech from public sources and are not affiliated with it. Spotted something wrong? Tell us.